Stock listing
KRX:068270 Celltrion, Inc. (셀트리온) 주가
Follow Celltrion, Inc. into a list and get an email when it puts out news.
Share price · KRX:068270
₩191,600 KRW +2,300 (+1.2%)
Close on Oct 30, 2026
- Day range
- ₩188,200 – ₩193,500 KRWOct 30, 2026
- Volume
- 514,543 sharesOct 30, 2026
- Market cap
- ₩43.69T KRWAt the close on Oct 30, 2026 · price × 228.0M shares outstanding
- 52-week range
- ₩158,500 – ₩239,048 KRWLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- ₩95.11B KRWMedian day 418,483 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · KRX:068270 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩191,600 | +2,300 | +1.2% | ₩191,200 | ₩193,500 | ₩188,200 | 514,543 | |
| ₩189,300 | -500 | -0.3% | ₩190,300 | ₩192,800 | ₩187,700 | 360,903 | |
| ₩189,800 | +1,200 | +0.6% | ₩189,600 | ₩194,200 | ₩189,200 | 418,176 | |
| ₩188,600 | -1,400 | -0.7% | ₩190,400 | ₩193,300 | ₩188,400 | 418,008 | |
| ₩190,000 | -4,400 | -2.3% | ₩192,900 | ₩196,900 | ₩188,000 | 418,790 | |
| ₩194,400 | +100 | +0.1% | ₩192,900 | ₩195,300 | ₩190,400 | 445,127 | |
| ₩194,300 | -3,300 | -1.7% | ₩195,700 | ₩198,400 | ₩191,200 | 507,504 | |
| ₩197,600 | +200 | +0.1% | ₩200,000 | ₩203,500 | ₩196,800 | 593,982 | |
| ₩197,400 | -800 | -0.4% | ₩195,600 | ₩202,000 | ₩195,100 | 693,751 | |
| ₩198,200 | +4,200 | +2.2% | ₩193,900 | ₩198,400 | ₩189,500 | 647,662 | |
| ₩194,000 | +11,900 | +6.5% | ₩184,500 | ₩195,500 | ₩183,800 | 1,099,634 | |
| ₩182,100 | +2,300 | +1.3% | ₩178,700 | ₩183,500 | ₩175,200 | 839,518 | |
| ₩179,800 | +100 | +0.1% | ₩179,900 | ₩185,000 | ₩178,300 | 466,550 | |
| ₩179,700 | -700 | -0.4% | ₩175,700 | ₩179,800 | ₩173,700 | 477,972 | |
| ₩180,400 | +800 | +0.4% | ₩182,000 | ₩184,400 | ₩179,800 | 386,216 | |
| ₩179,600 | -3,900 | -2.1% | ₩182,000 | ₩182,300 | ₩179,500 | 461,849 | |
| ₩183,500 | +1,100 | +0.6% | ₩182,800 | ₩184,000 | ₩181,200 | 254,258 | |
| ₩182,400 | -200 | -0.1% | ₩185,200 | ₩186,800 | ₩181,100 | 346,310 | |
| ₩182,600 | -1,000 | -0.5% | ₩183,000 | ₩183,750 | ₩180,600 | 319,980 | |
| ₩183,600 | +5,900 | +3.3% | ₩179,100 | ₩184,200 | ₩178,200 | 422,088 | |
| ₩177,700 | -1,200 | -0.7% | ₩179,800 | ₩179,900 | ₩177,700 | 352,051 | |
| ₩178,900 | +600 | +0.3% | ₩178,400 | ₩179,300 | ₩175,500 | 298,374 | |
| ₩178,300 | +900 | +0.5% | ₩178,400 | ₩180,700 | ₩177,600 | 267,873 | |
| ₩177,400 | -1,100 | -0.6% | ₩179,000 | ₩179,700 | ₩176,800 | 294,934 | |
| ₩178,500 | -2,900 | -1.6% | ₩181,800 | ₩182,200 | ₩178,100 | 337,067 | |
| ₩181,400 | +2,000 | +1.1% | ₩179,500 | ₩181,900 | ₩178,200 | 272,063 | |
| ₩179,400 | -900 | -0.5% | ₩182,000 | ₩182,800 | ₩179,400 | 718,200 | |
| ₩180,300 | +3,100 | +1.7% | ₩179,000 | ₩182,400 | ₩177,400 | 328,926 | |
| ₩177,200 | -300 | -0.2% | ₩178,800 | ₩178,800 | ₩176,200 | 259,646 | |
| ₩177,500 | -1,300 | -0.7% | ₩177,700 | ₩180,300 | ₩177,300 | 195,823 | |
| ₩178,800 | +600 | +0.3% | ₩176,500 | ₩180,400 | ₩174,600 | 396,196 | |
| ₩178,200 | -2,600 | -1.4% | ₩177,900 | ₩179,700 | ₩176,500 | 564,770 | |
| ₩180,800 | -2,300 | -1.3% | ₩181,800 | ₩183,500 | ₩180,100 | 742,053 | |
| ₩183,100 | 0 | 0.0% | ₩182,600 | ₩184,200 | ₩181,500 | 372,393 | |
| ₩183,100 | -3,200 | -1.7% | ₩187,500 | ₩188,800 | ₩182,900 | 482,451 | |
| ₩186,300 | -1,800 | -1.0% | ₩188,900 | ₩190,000 | ₩185,100 | 408,399 | |
| ₩188,100 | +1,000 | +0.5% | ₩189,000 | ₩189,100 | ₩186,600 | 270,580 | |
| ₩187,100 | +800 | +0.4% | ₩187,500 | ₩191,100 | ₩184,700 | 406,507 | |
| ₩186,300 | -1,700 | -0.9% | ₩185,200 | ₩189,800 | ₩184,200 | 299,403 | |
| ₩188,000 | -900 | -0.5% | ₩188,000 | ₩190,500 | ₩187,300 | 268,440 | |
| ₩188,900 | -1,800 | -0.9% | ₩188,000 | ₩191,300 | ₩185,000 | 643,636 | |
| ₩190,700 | -600 | -0.3% | ₩190,700 | ₩190,700 | ₩187,600 | 375,920 | |
| ₩191,300 | -2,100 | -1.1% | ₩194,000 | ₩195,400 | ₩190,600 | 255,697 | |
| ₩193,400 | +3,800 | +2.0% | ₩191,300 | ₩195,500 | ₩190,800 | 326,386 | |
| ₩189,600 | -4,400 | -2.3% | ₩193,600 | ₩194,600 | ₩188,900 | 358,412 | |
| ₩194,000 | +1,700 | +0.9% | ₩194,700 | ₩196,800 | ₩192,200 | 314,860 | |
| ₩192,300 | -1,800 | -0.9% | ₩192,100 | ₩193,100 | ₩187,600 | 354,956 | |
| ₩194,100 | 0 | 0.0% | ₩199,100 | ₩202,000 | ₩194,000 | 484,272 | |
| ₩194,100 | -1,400 | -0.7% | ₩193,900 | ₩196,400 | ₩190,700 | 375,772 | |
| ₩195,500 | -5,500 | -2.7% | ₩199,800 | ₩199,800 | ₩193,400 | 600,291 | |
| ₩201,000 | -1,000 | -0.5% | ₩200,500 | ₩203,500 | ₩198,900 | 341,446 | |
| ₩202,000 | 0 | 0.0% | ₩202,500 | ₩203,500 | ₩199,800 | 679,170 | |
| ₩202,000 | -8,500 | -4.0% | ₩208,500 | ₩212,000 | ₩200,500 | 926,438 | |
| ₩210,500 | +9,500 | +4.7% | ₩200,000 | ₩212,000 | ₩199,100 | 886,325 | |
| ₩201,000 | +1,700 | +0.9% | ₩197,700 | ₩202,000 | ₩194,850 | 533,999 | |
| ₩199,300 | +4,300 | +2.2% | ₩193,200 | ₩199,300 | ₩193,200 | 776,632 | |
| ₩195,000 | +4,700 | +2.5% | ₩191,000 | ₩196,300 | ₩189,800 | 801,664 | |
| ₩190,300 | +4,500 | +2.4% | ₩186,100 | ₩193,000 | ₩185,500 | 617,748 | |
| ₩185,800 | +3,600 | +2.0% | ₩182,100 | ₩185,800 | ₩180,300 | 521,154 | |
| ₩182,200 | -4,500 | -2.4% | ₩184,100 | ₩185,000 | ₩180,300 | 451,402 | |
| ₩186,700 | -3,300 | -1.7% | ₩189,200 | ₩189,300 | ₩183,700 | 1,127,709 | |
| ₩190,000 | +10,000 | +5.6% | ₩180,100 | ₩191,700 | ₩179,900 | 1,747,638 |
- Ticker
- KRX:068270
- Asset type
- Stock
- Exchange
- KRX
- Currency
- KRW
What changed lately
Latest news
Celltrion Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW 451.8Bn; Record Quarterly Revenue as New Product Growth and Cost Improvements Boost Profitability
Jul 26, 2026
Closed ₩178,700 (+0.6%) on Jul 27, 2026
Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
Apr 21, 2026
Closed ₩194,286 (+0.5%) on Apr 22, 2026
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
Mar 16, 2026
Closed ₩196,190 (+3.0%) on Mar 17, 2026
Zymfentra (Celltrion) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Mar 13, 2026
Closed ₩190,476 (-2.7%) on Mar 16, 2026
Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference
Jan 13, 2026
Closed ₩201,429 (-4.3%) on Jan 14, 2026
Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference
Jan 6, 2026
Closed ₩200,952 (-0.9%) on Jan 7, 2026
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
Dec 1, 2025
Closed ₩176,952 (+0.1%) on Dec 1, 2025
Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
Nov 26, 2025
Closed ₩178,476 (+2.7%) on Nov 26, 2025
Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases
Nov 3, 2025
Closed ₩166,286 (-0.6%) on Nov 3, 2025
U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
Oct 30, 2025
Closed ₩167,238 (+0.3%) on Oct 31, 2025
Celltrion, Inc. on 6ix
- News releases
- 9 in the last 12 months · 27 in all · newest Jul 27, 2026 · oldest 2021
Log in to ask 6ix AI your own questions about Celltrion, Inc.